H
Hefei Zhongke Presheng Biomedical Technology
Specialized cell engineering services for targeted drug development
About Hefei Zhongke Presheng Biomedical Technology
Hefei Zhongke Presheng Biomedical Technology Co., Ltd. is a high-tech enterprise established in 2015, with backing from state-owned industrial capital and research support from the Hefei Institutes of Physical Science, Chinese Academy of Sciences. The company was co-founded by Liu Qingsong, Liu Jing, Wang Wenchao, and Ren Tao, four of the scientists known as the 'Harvard Eight'. It focuses on core cell engineering technologies to address bottlenecks in the biopharmaceutical field, particularly in oncology.
The company provides technical support services for drug research and development institutions and offers precision medicine consulting for medical establishments. Its business model centers on creating and utilizing extensive cell banks to support preclinical drug screening, efficacy evaluation, and personalized cancer treatment. Key assets include the Ba/F3 cancer kinase target engineering cell bank, which is among the world's largest, and the China Living Primary Cancer Cell Bank (LPCB). These resources are used for high-throughput drug sensitivity screening and to develop patient-derived xenograft (PDX), patient-derived organoid (PDO), and patient-derived cell (PDC) models. This infrastructure supports the development of novel targeted drugs and provides critical data for clinical precision medicine.
Zhongke Presheng serves the broader health industry by providing the foundational resources for the entire biopharmaceutical development chain. It has established collaborations with major hospitals in Anhui province, delivering personalized medication plans for hundreds of cancer patients based on its proprietary drug sensitivity testing technology. The company's mission is to advance precision oncology and make it more accessible, contributing to the 'Healthy China' national strategy.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES C✓Equity / VC | Nov 2023 | $14M | $55M | Sunland fund | ↗ |
| SERIES B✓Equity / VC | May 2022 | $0 | — | Hefei Industry Investment Group | — |
Growth signals
Latest recorded traffic for Hefei Zhongke Presheng Biomedical Technology is 920 monthly website visits, up 2966.7% over the last three months. Hefei Zhongke Presheng Biomedical Technology's team declined 16.7% over the past year.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Hefei Zhongke Presheng Biomedical Technology in its local ecosystem
The Hefei Zhongke Presheng Biomedical Technology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
- ACAnhui High-tech Venture Capital
Series A1 investor entered at this stage
- HGHefei Industry Investment Group
Series B and later1 investor entered at this stage
Sunland fund
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Hefei Zhongke Presheng Biomedical Technology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Hefei Zhongke Presheng Biomedical Technology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.